BlackRock, Inc. - 31 Mar 2025 SCHEDULE 13G/A Report for Verve Therapeutics, Inc. Common Stock (VERV)

Filing Manager
BlackRock, Inc.
Reporting Manager
BlackRock, Inc.
Security
Verve Therapeutics, Inc. Common Stock
Symbol
VERV
Shares outstanding
88,253,586 shares
Disclosed Ownership
6,177,751 shares
Ownership
7%
Form type
SCHEDULE 13G/A
Filing time
17 Apr 2025, 17:40:23 UTC
Date of event
31 Mar 2025
SEC
View on sec.gov

Quoteable Key Fact

"BlackRock, Inc. disclosed 7% ownership in Verve Therapeutics, Inc. Common Stock (VERV) on 31 Mar 2025."

Quick Takeaways

  • BlackRock, Inc. filed SCHEDULE 13G/A for Verve Therapeutics, Inc. Common Stock (VERV).
  • Disclosed ownership: 7%.
  • Date of event: 31 Mar 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 17 Apr 2025, 17:40.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (1)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
BlackRock, Inc. 7% 6,177,751 6,054,915 0 Spencer Fleming Managing Director
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .